297 related articles for article (PubMed ID: 16108855)
1. Health-economic comparison of continuous subcutaneous insulin infusion with multiple daily injection for the treatment of Type 1 diabetes in the UK.
Roze S; Valentine WJ; Zakrzewska KE; Palmer AJ
Diabet Med; 2005 Sep; 22(9):1239-45. PubMed ID: 16108855
[TBL] [Abstract][Full Text] [Related]
2. Continuous subcutaneous insulin infusion versus multiple daily injections of insulin: economic comparison in adult and adolescent type 1 diabetes mellitus in Australia.
Cohen N; Minshall ME; Sharon-Nash L; Zakrzewska K; Valentine WJ; Palmer AJ
Pharmacoeconomics; 2007; 25(10):881-97. PubMed ID: 17887808
[TBL] [Abstract][Full Text] [Related]
3. Health economic comparison between continuous subcutaneous insulin infusion and multiple daily injections of insulin for the treatment of adult type 1 diabetes in Canada.
St Charles ME; Sadri H; Minshall ME; Tunis SL
Clin Ther; 2009 Mar; 31(3):657-67. PubMed ID: 19393856
[TBL] [Abstract][Full Text] [Related]
4. A cost-effectiveness analysis of continuous subcutaneous insulin injection versus multiple daily injections in type 1 diabetes patients: a third-party US payer perspective.
St Charles M; Lynch P; Graham C; Minshall ME
Value Health; 2009; 12(5):674-86. PubMed ID: 19171006
[TBL] [Abstract][Full Text] [Related]
5. Long-term health economic benefits of sensor-augmented pump therapy vs continuous subcutaneous insulin infusion alone in type 1 diabetes: a U.K. perspective.
Roze S; Smith-Palmer J; Valentine WJ; Cook M; Jethwa M; de Portu S; Pickup JC
J Med Econ; 2016; 19(3):236-42. PubMed ID: 26510389
[TBL] [Abstract][Full Text] [Related]
6. [Cost-effectiveness of continuous subcutaneous insulin infusion therapy for type 1 diabetes].
Nørgaard K; Sohlberg A; Goodall G
Ugeskr Laeger; 2010 Jul; 172(27):2020-5. PubMed ID: 20594535
[TBL] [Abstract][Full Text] [Related]
7. Continuous subcutaneous insulin infusion versus multiple daily injection regimens in children and young people at diagnosis of type 1 diabetes: pragmatic randomised controlled trial and economic evaluation.
Blair JC; McKay A; Ridyard C; Thornborough K; Bedson E; Peak M; Didi M; Annan F; Gregory JW; Hughes DA; Gamble C;
BMJ; 2019 Apr; 365():l1226. PubMed ID: 30944112
[TBL] [Abstract][Full Text] [Related]
8. Clinical Outcome and Cost-Effectiveness Analysis of CSII Versus MDI in Children and Adolescent With Type 1 Diabetes Mellitus in a Public Health Care System of China.
Hu S; Yang H; Chen Z; Leng X; Li C; Qiao L; Lv W; Li T
Front Endocrinol (Lausanne); 2021; 12():604028. PubMed ID: 33859614
[TBL] [Abstract][Full Text] [Related]
9. Health-economic analysis of real-time continuous glucose monitoring in people with Type 1 diabetes.
Roze S; Saunders R; Brandt AS; de Portu S; Papo NL; Jendle J
Diabet Med; 2015 May; 32(5):618-26. PubMed ID: 25483869
[TBL] [Abstract][Full Text] [Related]
10. Continuous subcutaneous insulin infusion versus multiple daily injections in children and young people at diagnosis of type 1 diabetes: the SCIPI RCT.
Blair J; McKay A; Ridyard C; Thornborough K; Bedson E; Peak M; Didi M; Annan F; Gregory JW; Hughes D; Gamble C
Health Technol Assess; 2018 Aug; 22(42):1-112. PubMed ID: 30109847
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of continuous subcutaneous insulin infusion versus multiple daily injections of insulin in Type 1 diabetes: a systematic review.
Roze S; Smith-Palmer J; Valentine W; de Portu S; Nørgaard K; Pickup JC
Diabet Med; 2015 Nov; 32(11):1415-24. PubMed ID: 25962621
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of detemir-based basal/bolus therapy versus NPH-based basal/bolus therapy for type 1 diabetes in a UK setting: an economic analysis based on meta-analysis results of four clinical trials.
Palmer AJ; Roze S; Valentine WJ; Smith I; Wittrup-Jensen KU
Curr Med Res Opin; 2004 Nov; 20(11):1729-46. PubMed ID: 15537473
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of continuous subcutaneous insulin infusion in people with type 2 diabetes in the Netherlands.
Roze S; Duteil E; Smith-Palmer J; de Portu S; Valentine W; de Brouwer BF; Reznik Y; de Valk HW
J Med Econ; 2016 Aug; 19(8):742-9. PubMed ID: 26985982
[TBL] [Abstract][Full Text] [Related]
14. Clinical effectiveness and cost-effectiveness of continuous subcutaneous insulin infusion for diabetes: systematic review and economic evaluation.
Cummins E; Royle P; Snaith A; Greene A; Robertson L; McIntyre L; Waugh N
Health Technol Assess; 2010 Feb; 14(11):iii-iv, xi-xvi, 1-181. PubMed ID: 20223123
[TBL] [Abstract][Full Text] [Related]
15. The cost-effectiveness of continuous subcutaneous insulin infusion compared with multiple daily injections for the management of diabetes.
Scuffham P; Carr L
Diabet Med; 2003 Jul; 20(7):586-93. PubMed ID: 12823242
[TBL] [Abstract][Full Text] [Related]
16. Exenatide versus insulin glargine in patients with type 2 diabetes in the UK: a model of long-term clinical and cost outcomes.
Ray JA; Boye KS; Yurgin N; Valentine WJ; Roze S; McKendrick J; Tucker DM; Foos V; Palmer AJ
Curr Med Res Opin; 2007 Mar; 23(3):609-22. PubMed ID: 17355742
[TBL] [Abstract][Full Text] [Related]
17. Comparison between a multiple daily insulin injection regimen (basal once-daily glargine plus mealtime lispro) and continuous subcutaneous insulin infusion (lispro) using continuous glucose monitoring in metabolically optimized type 1 diabetes patients: A randomized open-labelled parallel study.
Ruiz-de-Adana MS; Dominguez-Lopez ME; Gonzalez-Molero I; Machado A; Martin V; Cardona I; de-la-Higuera M; Tapia MJ; Soriguer F; Anarte MT; Rojo-Martínez G
Med Clin (Barc); 2016 Mar; 146(6):239-46. PubMed ID: 26656958
[TBL] [Abstract][Full Text] [Related]
18. PROactive 06: cost-effectiveness of pioglitazone in Type 2 diabetes in the UK.
Valentine WJ; Bottomley JM; Palmer AJ; Brändle M; Foos V; Williams R; Dormandy JA; Yates J; Tan MH; Massi-Benedetti M;
Diabet Med; 2007 Sep; 24(9):982-1002. PubMed ID: 17593245
[TBL] [Abstract][Full Text] [Related]
19. Cost-Effectiveness Analysis of the MiniMed 670G Hybrid Closed-Loop System Versus Continuous Subcutaneous Insulin Infusion for Treatment of Type 1 Diabetes.
Jendle J; Pöhlmann J; de Portu S; Smith-Palmer J; Roze S
Diabetes Technol Ther; 2019 Mar; 21(3):110-118. PubMed ID: 30785311
[TBL] [Abstract][Full Text] [Related]
20. Clinical and economic benefits of integrated pump/CGM technology therapy in patients with type 1 diabetes in Colombia.
Gomez AM; Alfonso-Cristancho R; Orozco JJ; Lynch PM; Prieto D; Saunders R; Roze S; Valencia JE
Endocrinol Nutr; 2016 Nov; 63(9):466-474. PubMed ID: 27595241
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
